Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of CHOP-Rituximab Augmented With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

NCT00455897 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00455897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00455897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of CHOP-Rituximab Augmented With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2006
Completion date
July 31, 2011
Enrollment
3 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, b-cell, lymphoma, diffuse, lymphoma, non-hodgkin